Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An Updated Economic Evaluation of HLA ‐B*58:01 Genotype Testing in Gouty Patients for Preventing Severe Allopurinol Hypersensitivity in Thailand

1 Aug 2025

Abstract excerpt

OBJECTIVE: Human Leukocyte Antigen (HLA), specifically HLA-B*58:01, testing before allopurinol initiation in patients with gout in Thailand was previously shown to be cost-effective. However, several drugs are available in the treatment of gout in Thailand, so the updated cost-effectiveness analysis is warranted. This study aimed to update the cost-effectiveness of HLA-B*58:01 testing before allopurinol...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug-Induced Adverse Reactions
Share to Gout, Hyperuricemia, Uric Acid
Share to Rheumatoid Arthritis Research and Therapies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40829930
DOI: 10.1002/acr2.70093

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An Updated Economic Evaluation of HLA ‐B*58:01 Genotype Testing in Gouty Patients for Preventing Severe Allopurinol Hypersensitivity in ThailandPMID 40829930Read ↗

Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.Semantic proximity Read ↗

Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.Semantic proximity Read ↗

Cost minimization of HLA-B*1502 screening before prescribing carbamazepine in Thailand.Semantic proximity Read ↗

Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea.Semantic proximity Read ↗

Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?Semantic proximity Read ↗

Cost-effectiveness analysis of genotyping for HLA-B*15:02 in Indonesian patients with epilepsy using a generic model.Semantic proximity Read ↗

Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.Semantic proximity Read ↗

HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.Semantic proximity Read ↗

Evolution of HLA-B Pharmacogenomics and the Importance of PGx Data Integration in Health Care System: A 10 Years Retrospective Study in ThailandSemantic proximity Read ↗

COST-EFFECTIVENESS ANALYSIS OF HLA-B*15:02 SCREENING BEFORE TREATMENT OF EPILEPSY IN INDONESIASemantic proximity Read ↗

Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.Semantic proximity Read ↗

Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescriptionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.